183 related articles for article (PubMed ID: 29186089)
1. Correlation Between Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphisms and Pemetrexed Chemotherapy Efficacy/Toxicity in Non-Squamous Non-Small Cell Lung Cancer.
Lan G; Lin L; Chen X; Chen L; Chen X
Med Sci Monit; 2017 Nov; 23():5683-5689. PubMed ID: 29186089
[TBL] [Abstract][Full Text] [Related]
2. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.
Kucharczyk T; Krawczyk P; Powrózek T; Kowalski DM; Ramlau R; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Krzakowski M; Milanowski J
Pathol Oncol Res; 2016 Jan; 22(1):49-56. PubMed ID: 26277606
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
4. Allele and Genotype Frequencies of the Polymorphic Methylenetetrahydrofolate Reductase and Lung Cancer in ther Jordanian Population: a Case Control Study.
Al-Motassem Y; Shomaf M; Said I; Berger S; Ababneh N; Diab O; Obeidat N; Awidi A
Asian Pac J Cancer Prev; 2015; 16(8):3101-9. PubMed ID: 25921104
[TBL] [Abstract][Full Text] [Related]
5. Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population.
Hong W; Wang K; Zhang YP; Kou JY; Hong D; Su D; Mao WM; Yu XM; Xie FJ; Wang XJ
J Zhejiang Univ Sci B; 2013 Mar; 14(3):207-15. PubMed ID: 23463763
[TBL] [Abstract][Full Text] [Related]
6. Methylenetetrahydrofolate reductase C677T polymorphism in patients with lung cancer in a Korean population.
Cui LH; Shin MH; Kim HN; Song HR; Piao JM; Kweon SS; Choi JS; Yun WJ; Kim YC; Oh IJ; Kim KS
BMC Med Genet; 2011 Feb; 12():28. PubMed ID: 21342495
[TBL] [Abstract][Full Text] [Related]
7. Association of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism with primary glaucoma in Saudi population.
Al-Shahrani H; Al-Dabbagh N; Al-Dohayan N; Arfin M; Al-Asmari M; Rizvi S; Al-Asmari A
BMC Ophthalmol; 2016 Sep; 16(1):156. PubMed ID: 27585654
[TBL] [Abstract][Full Text] [Related]
8. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms in oral squamous cell carcinoma in south-east Iran.
Miri-Moghaddam E; Saravani S; Garme Y; Khosravi A; Bazi A; Motazedian J
J Oral Pathol Med; 2016 Feb; 45(2):96-100. PubMed ID: 26218632
[TBL] [Abstract][Full Text] [Related]
9. Association of Methylenetetrahydrofolate Reductase C677T and A1298C Gene Polymorphisms With Recurrent Pregnancy Loss in Syrian Women.
Al-Achkar W; Wafa A; Ammar S; Moassass F; Jarjour RA
Reprod Sci; 2017 Sep; 24(9):1275-1279. PubMed ID: 28814189
[TBL] [Abstract][Full Text] [Related]
10. Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis.
Zhu N; Gong Y; He J; Xia J; Chen X
Yonsei Med J; 2013 Nov; 54(6):1384-93. PubMed ID: 24142642
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and meta-analysis of the predictive power of
Bai Y; Ma X; Zhang YH
J Chemother; 2022 Nov; 34(7):472-482. PubMed ID: 34877924
[TBL] [Abstract][Full Text] [Related]
12. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC.
Cui LH; Yu Z; Zhang TT; Shin MH; Kim HN; Choi JS
Pharmacogenomics; 2011 Jun; 12(6):797-808. PubMed ID: 21605004
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of the polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase gene in lung cancer.
Takehara A; Kawakami K; Ohta N; Oyama K; Ota Y; Oda M; Watanabe G
Anticancer Res; 2005; 25(6C):4455-61. PubMed ID: 16334126
[TBL] [Abstract][Full Text] [Related]
14. [Polymorphism of methylenetetrahydrofolate reductase and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy].
Gao CM; Lu JW; Toshiro T; Wu JZ; Cao HX; Chen HQ; Feng JF; Kazuo T
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Dec; 25(12):1054-8. PubMed ID: 15769364
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.
Krawczyk P; Kucharczyk T; Kowalski DM; Powrózek T; Ramlau R; Kalinka-Warzocha E; Winiarczyk K; Knetki-Wróblewska M; Wojas-Krawczyk K; Kałakucka K; Dyszkiewicz W; Krzakowski M; Milanowski J
J Cancer Res Clin Oncol; 2014 Dec; 140(12):2047-57. PubMed ID: 25028118
[TBL] [Abstract][Full Text] [Related]
16. 5,10-Methylenetetrahydrofolate reductase C677T gene polymorphism in Behcet's patients with or without ocular involvement.
Ozkul Y; Evereklioglu C; Borlu M; Taheri S; Calis M; Dündar M; Ilhan O
Br J Ophthalmol; 2005 Dec; 89(12):1634-7. PubMed ID: 16299146
[TBL] [Abstract][Full Text] [Related]
17. [Arterial Hypertension and Methylenetetrahydrofolate Reductase C677T Gene Polymorphism].
Pavlova OS; Ogurtsova SE; Liventseva MM; Korobko IY; Mrochek AG
Kardiologiia; 2018 Oct; (10):5-11. PubMed ID: 30359211
[TBL] [Abstract][Full Text] [Related]
18. A folylpoly-γ-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer.
Fukuda S; Oguri T; Kunii E; Sone K; Uemura T; Takakuwa O; Maeno K; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
Lung Cancer; 2016 Dec; 102():15-20. PubMed ID: 27987582
[TBL] [Abstract][Full Text] [Related]
19. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.
Alberola V; Sarries C; Rosell R; Taron M; de las Peñas R; Camps C; Massuti B; Insa A; Garcia-Gomez R; Isla D; Artal A; Muñoz MA; Cobo M; Bover I; Gonzalez-Larria JL; Terrasa J; Almenar D; Barcelo R; Diz P; Sanchez-Ronco M; Sanchez JJ
Clin Lung Cancer; 2004 May; 5(6):360-5. PubMed ID: 15217535
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
